Tag
#JPM
-
2026
-
iRhythm Technologies, Inc. Shares Preliminary Fourth Quarter 2025 Highlights and Business Update at the 44th Annual J.P. Morgan Healthcare Conference
-
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference
-
Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference
-
Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
-
BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference
-
Day One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Provides 2026 Net Product Revenue Guidance
-
Argo Biopharma to Present at the 44th Annual J.P. Morgan Healthcare Conference
-
Umicore – Transparency notification by JP Morgan Asset Management Holdings Inc.
-
CorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
-
iOnctura CEO to present at the 2026 J.P. Morgan Healthcare Conference
-
Averna Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
-
Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
-
Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference
-
Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
-
CREATE Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference
-
SonoThera Launches $125M Series B at 44th J.P. Morgan Healthcare Conference to Advance Multiple Genetic Medicine Programs Toward First-in-Human Studies
-
ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference
-
Zifo at JPM Healthcare Conference 2026: Why Technology Alone Cannot Deliver the AI Promise
-
Encoded Therapeutics Highlights Progress in Dravet Syndrome Program and Pipeline Ahead of Company Presentation at 44th Annual J.P. Morgan Healthcare Conference
-
Immorta Bio Doubles Mouse Lifespan Using Combination Senolytic and Regenerative Therapy in Validated Aging Models
-
32 Biosciences to Launch $40 Million Series A at J.P. Morgan to Advance First-in-Class GI Mucosal-Immune Therapeutics
-
Avenacy Provides Update on Business Progress and Announces 2026 Strategic Priorities Ahead of 44th Annual J.P. Morgan Healthcare Conference
-
Flare Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
-
Enovis to Participate in the 44th Annual J.P. Morgan Healthcare Conference
-
Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook